Welcome to our dedicated page for Surgery Partners SEC filings (Ticker: SGRY), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Surgery Partners, Inc. filings document the public-company record for a healthcare services operator focused on short-stay surgical facilities. Form 8-K reports furnish quarterly and annual results, non-GAAP reconciliations, guidance updates and Regulation FD materials related to the company’s surgical facility operations.
The filing record also covers governance and capital structure. Proxy materials describe director elections, executive compensation and stockholder voting matters, while current reports disclose debt financing through Surgery Center Holdings, Inc., supplemental indentures for senior notes, leadership appointments, employment agreements and the company’s Nasdaq-listed common stock.
Surgery Partners, Inc. (SGRY) has submitted a Form 144 reporting a proposed sale of 150,000 common shares through UBS Financial Services with an aggregate market value of $3,294,454.97. The shares were acquired on 09/18/2025 via an equity option exercise from Surgery Partners, Inc., and the planned sale is listed for 09/18/2025 on NASDAQ. The filing also discloses multiple recent sales by Wayne DeVeydt between 08/21/2025 and 09/17/2025, including transactions of 100,000 shares on 08/21/2025 and 09/11/2025 and several smaller sales, each with stated gross proceeds. The notice includes the signers representation that they are not aware of undisclosed material adverse information about the issuer.
Surgery Partners, Inc. (SGRY) has submitted a Form 144 reporting a proposed sale of 150,000 common shares through UBS Financial Services with an aggregate market value of $3,294,454.97. The shares were acquired on 09/18/2025 via an equity option exercise from Surgery Partners, Inc., and the planned sale is listed for 09/18/2025 on NASDAQ. The filing also discloses multiple recent sales by Wayne DeVeydt between 08/21/2025 and 09/17/2025, including transactions of 100,000 shares on 08/21/2025 and 09/11/2025 and several smaller sales, each with stated gross proceeds. The notice includes the signers representation that they are not aware of undisclosed material adverse information about the issuer.
Surgery Partners, Inc. (SGRY) Form 144 reports a proposed sale of 85,785 common shares through UBS Financial Services with an aggregate market value of $1,873,875, with an approximate sale date of 09/17/2025 on NASDAQ. The shares were acquired on 09/17/2025 by equity compensation from Surgery Partners, Inc., with payment described as an equity option exercise. The filing also discloses multiple recent open-market sales by Wayne DeVeydt totaling 392,579 shares between 08/21/2025 and 09/16/2025 generating aggregate gross proceeds reported in the table. The signee represents no undisclosed material adverse information.
Surgery Partners, Inc. (SGRY) Form 144 reports a proposed sale of 85,785 common shares through UBS Financial Services with an aggregate market value of $1,873,875, with an approximate sale date of 09/17/2025 on NASDAQ. The shares were acquired on 09/17/2025 by equity compensation from Surgery Partners, Inc., with payment described as an equity option exercise. The filing also discloses multiple recent open-market sales by Wayne DeVeydt totaling 392,579 shares between 08/21/2025 and 09/16/2025 generating aggregate gross proceeds reported in the table. The signee represents no undisclosed material adverse information.
Surgery Partners, Inc. (SGRY) Form 144 shows a proposed sale of 25,000 common shares through UBS on 09/16/2025, with an aggregate market value reported as $541,517.60. The shares were acquired on 09/16/2025 via equity compensation and the payment/nature is listed as an equity option exercise. The filing also discloses that the same account (Wayne DeVeydt) sold a total of 367,579 common shares in the prior three months for aggregate gross proceeds of $8,267,200. The filing lists 128,209,410 shares outstanding, and the planned sale is to occur on the NASDAQ through UBS Financial Services.
Surgery Partners, Inc. reported that Harrison R. Bane, its National Group President, has decided to resign from his current role, effective October 3, 2025. The company states that Mr. Bane’s resignation is not due to any disagreement with Surgery Partners on operations, policies, or practices, indicating this is a personal or career decision rather than a dispute with the company.
Surgery Partners, Inc. (SGRY) Form 144 notice records a proposed sale of 100,000 shares of common stock through UBS Financial Services, scheduled approximately for 09/11/2025. The shares were acquired on 09/11/2025 via equity compensation (equity option exercise) from Surgery Partners, Inc. The filing reports the aggregate market value for the 100,000 shares as $2,201,000 and shows 128,209,410 shares outstanding. The filer also disclosed multiple recent sales by Wayne DeVeydt between 08/21/2025 and 09/08/2025, listing transaction sizes and gross proceeds for each sale. The notice includes the standard representations that the seller is not aware of any undisclosed material adverse information and that intentional misstatements are unlawful.
Surgery Partners, Inc. (SGRY) Form 144: The filing notifies a proposed sale of 2,014 common shares through UBS Financial Services with an aggregate market value of $45,217, to be sold on 09/08/2025. The shares were acquired the same day via equity compensation (equity option exercise) from Surgery Partners, Inc.
The filing also discloses prior sales by Wayne DeVeydt between 08/21/2025 and 09/05/2025 totaling 236,865 common shares for gross proceeds of $5,392,323. The form includes the mandatory representation that the seller is not aware of any undisclosed material adverse information.
Surgery Partners insider sale to cover tax withholding reduced holdings. National Group President Harrison R. Bane reported two stock sale transactions on 09/04/2025 at $22.48 per share, disposing of 5,726 and 3,613 shares respectively to satisfy tax withholding related to restricted stock vesting on 09/01/2025. After the sales, he beneficially owned 117,181 shares. The Form 4 was signed by an attorney-in-fact on 09/08/2025.
Surgery Partners, Inc. (SGRY) Form 144 shows an insider notice for the proposed sale of 25,000 shares of common stock to be executed through UBS Financial Services on 09/05/2025 with an aggregate market value listed at $563,700. The filing states those 25,000 shares were acquired the same day, 09/05/2025, as equity compensation from Surgery Partners, Inc., and the payment/transfer is described as an equity option exercise. The filing also lists multiple recent open-market sales by the same individual, Wayne DeVeydt, during August and early September 2025, including transactions of 100,000; 25,000; 11,865; and several 25,000-share sales with disclosed gross proceeds for each trade. The notice includes the standard insider attestation that no undisclosed material adverse information is known.
Surgery Partners, Inc. (SGRY) Form 144 shows a proposed sale of 25,000 common shares through UBS Financial Services on 09/04/2025 with an aggregate market value of $562,766. The shares were acquired the same day via equity compensation from Surgery Partners and were paid for by an equity option exercise. The filing also discloses that Wayne DeVeydt sold a total of 187,865 common shares in the prior three months for aggregate gross proceeds of $4,265,885 across five transactions dated 08/21/2025 through 09/03/2025. The filer affirms no undisclosed material adverse information.
Surgery Partners, Inc. (SGRY) Form 144: This notice reports a proposed sale of 9,339 shares of common stock to be executed through UBS Financial Services Inc. on or about 09/04/2025 with an aggregate market value of $209,944. The shares were acquired on 09/01/2025 through equity vesting as equity compensation from Surgery Partners, Inc.
The filing lists 128,209,410 shares outstanding for the issuer. Several standard filer and issuer identification fields (including the name of the person for whose account the securities are to be sold and filer CIK/CCC) are not populated in the provided content.